WASHINGTON, Nov. 24, 2015 (GLOBE NEWSWIRE) -- Morgan Lewis is serving as lead U.S. antitrust counsel to Pfizer in its proposed combination with Allergan, which will establish a new global biopharmaceutical leader.
The Morgan Lewis team is led by partners Scott Stempel and Harry Robins. Support is provided by partner Clay Everett and associates David Brenneman, Martin d'Halluin, Katie Glynn, and Maria Luisa Di Lauro.
When completed, the transaction will be the largest pharmaceutical industry M &A transaction in history and among the largest M &A transactions of any type. Including this deal, the Morgan Lewis antitrust team has worked on three of the seven largest pharmaceutical transactions ever.
The transaction is expected to close in the second half of 2016. Pfizer's press release can be read here.
About Morgan, Lewis & Bockius LLP
Founded in 1873, Morgan Lewis offers more than 2,000 lawyers, patent agents, benefits advisers, regulatory scientists, and other specialists—in 28 offices across the United States, Europe, Asia, and the Middle East. The firm provides comprehensive litigation, corporate, transactional, regulatory, intellectual property, and labor and employment legal services to clients of all sizes—from globally established industry leaders to just-conceived start-ups. For more information about Morgan Lewis or its practices, please visit us online at www.morganlewis.com.
Morgan Lewis Serves as Lead U.S. Antitrust Counsel to Pfizer in Blockbuster Combination with Allergan
| Source: Morgan, Lewis & Bockius LLP